CSIMarket
 
Reata Pharmaceuticals Inc   (RETA)
Other Ticker:  
 
 
Price: $172.3600 $0.04 0.023%
Day's High: $172.46 Week Perf: 0.15 %
Day's Low: $ 172.32 30 Day Perf: 2.14 %
Volume (M): 1,989 52 Wk High: $ 172.46
Volume (M$): $ 342,738 52 Wk Avg: $115.42
Open: $172.34 52 Wk Low: $26.26



 Market Capitalization (Millions $) 7,154
 Shares Outstanding (Millions) 42
 Employees 339
 Revenues (TTM) (Millions $) 23
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -98
 Capital Exp. (TTM) (Millions $) 1

Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc. is a biopharmaceutical company that is dedicated to the discovery, development, and commercialization of novel therapeutics for patients with serious or life-threatening diseases. The company was founded in 2002 and is headquartered in Texas, United States.

Reata is focused on developing small molecule drugs that target specific signaling pathways that underlie diseases such as chronic kidney disease, rare genetic diseases, and various forms of cancer. The company's approach is to develop drugs that target specific cellular pathways that are involved in disease progression, including oxidative stress, inflammation, and cellular metabolism.

One of Reata's lead drug candidates is bardoxolone methyl, which is under development for multiple rare and severe conditions. It is a potent activator of a transcription factor called Nrf2, which plays a key role in regulating the body's response to oxidative stress and inflammation. Bardoxolone methyl is currently in clinical trials for chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome.

Another promising drug candidate in Reata's pipeline is omaveloxolone, which is being studied for the treatment of Friedreich's ataxia, a rare genetic disease that affects the nervous system and causes balance problems, difficulty walking, and other symptoms. Omaveloxolone is also being evaluated for the treatment of mitochondrial myopathy, a rare disorder that affects the production of energy within cells.

In addition to its clinical development programs, Reata has a growing portfolio of preclinical programs focused on developing drugs for various types of cancer, including pancreatic cancer and other solid tumors. The company's preclinical pipeline also includes drug candidates for the treatment of rare inherited diseases such as polycystic kidney disease.

Reata has a strong track record of advancing its drug candidates through clinical development and securing FDA approvals. The company has a strategic partnership with Kyowa Kirin Co. Ltd., a global pharmaceutical company, to develop and commercialize bardoxolone methyl in certain territories outside of the United States.

Overall, Reata Pharmaceuticals is a highly innovative biopharmaceutical company that is making significant progress in the development of novel therapeutics for patients with serious and life-threatening diseases. The company's focus on developing drugs that target specific cellular pathways involved in disease progression has the potential to transform the treatment of a range of diseases and improve outcomes for patients.


   Company Address: 5320 Legacy Drive Plano 75024 TX
   Company Phone Number: 865-2219   Stock Exchange / Ticker: NASDAQ RETA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc Surges in Revenue with Impressive 2885% Growth, but Industry Context Raises Concerns

In the most recent fiscal period, Reata Pharmaceuticals Inc (RETA) experienced an astonishing revenue advance of 2885.039% year on year, reaching $22.75 million. This substantial growth in revenue has sparked optimism among investors, as the company managed to turn around its earnings by exhibiting earnings per share (EPS) of $4.65. However, upon closer examination, it becomes clear that there are several reasons to be bearish about RETA's future prospects.
While it is true that Reata Pharmaceuticals Inc achieved a higher rate of revenue growth compared to its competitors in the Major Pharmaceutical Preparations sector, it is essential to consider the broader industry context. In the second quarter of 2023, most businesses in the Major Pharmaceutical Preparations industry experienced a modest revenue advance of only 0.89% from the second quarter of 2022. This indicates that RETA's exceptional revenue growth may be an outlier rather than a reflection of the overall industry performance.

Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc Faces Devastating -78.665% Revenue Slide in First Quarter of 2023

The stock market has been buzzing with the latest news from Reata Pharmaceuticals Inc. While there has been a slight dip in their revenue per employee on a trailing twelve month basis, the company remains at the forefront of their peers in the healthcare sector, achieving the highest revenue/employee. With 339 employees, this is an impressive feat that deserves recognitionHowever, the recent Mar 31, 2023 report has come as a shock to many. The revenue saw a significant decline of -78.665% to a mere $0.20 million. This has resulted in the net deficit per share extending to $-3.14, which is a significant drop from the comparable reporting period a year prior. The fiscal span ending March 31, 2023, saw Reata Pharmaceuticals Inc incurring a net deficit of $-116.117 million, which is significantly more substantial than $-73.842 million a year ago.
Despite these challenging times, it's essential to note that the company is expected to report next financial results on August 07, 2023. This gives investors hope that things could improve drastically in the coming months. It's also essential to remember that the company is still regarded as the best in class within their peers in the healthcare sector.
Reata Pharmaceuticals Inc's overall ranking has deteriorated compared to the fourth quarter of 2022, and while this is something that they need to improve on, the fact remains that they are still doing better than many of their peers in the market.
In conclusion, while the recent report may have been disappointing news for investors, there is still hope for Reata Pharmaceuticals Inc. The company remains one of the leading names in the healthcare sector and has achieved an impressive record in terms of revenue/employee. With the next financial results report due in August, investors can remain optimistic about the future of the company.






 

Reata Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com